{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T05:01:33Z","timestamp":1791349293512,"version":"4.3.1"},"reference-count":79,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:p>Cardiovascular disease is the global leading cause of death and hypercholesterolemia is implicated as one of its top contributors. Moreover, there is growing recognition that lower low-density lipoprotein cholesterol levels offer greater protection against cardiovascular disease. Statins are the first-line lipid-lowering agents for both primary and secondary prevention of cardiovascular disease in patients with hypercholesterolemia. However, statin resistance and intolerance lead to undertreatment in patients who would likely derive the most benefit from antihyperlipidemic drugs. Several non-statin therapies are increasingly prescribed to such patients, most commonly ezetimibe and the PCSK9 monoclonal antibodies, but numerous other options have been developed in recent years and investigations into new therapies are ongoing. The use of these non-statin therapies requires the clinician to take a highly personalized approach to cholesterol reduction in complex patients. In this review, we describe current non-statin options for statin-resistant and statin-intolerant patients in addition to areas of active research.<\/jats:p>","DOI":"10.1097\/crd.0000000000000498","type":"journal-article","created":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T14:11:32Z","timestamp":1666966292000},"page":"51-56","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":11,"title":["Antihyperlipidemic Treatment Options in Statin Resistance and Intolerance"],"prefix":"10.1097","volume":"32","author":[{"given":"Alexandrina","family":"Danilov","sequence":"first","affiliation":[{"name":"New York Medical College"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William H.","family":"Frishman","sequence":"additional","affiliation":[{"name":"Department of Medicine, New York Medical College, and Department of Cardiology, Westchester Medical Center and New York Medical College, Valhalla, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilbert S.","family":"Aronow","sequence":"additional","affiliation":[{"name":"Department of Medicine, New York Medical College, and Department of Cardiology, Westchester Medical Center and New York Medical College, Valhalla, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,6,7]]},"reference":[{"key":"R1-20250619","doi-asserted-by":"crossref","first-page":"e153","DOI":"10.1161\/CIR.0000000000001052","article-title":"Heart disease and stroke statistics-2022 update: a report from the American Heart Association.","volume":"145","author":"Tsao","year":"2022","journal-title":"Circulation"},{"key":"R2-20250619","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel.","volume":"38","author":"Ference","year":"2017","journal-title":"Eur Heart J"},{"key":"R3-20250619","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0140-6736(04)17018-9","article-title":"Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study.","volume":"364","author":"Yusuf","year":"2004","journal-title":"Lancet"},{"key":"R4-20250619","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1001\/jama.1986.03380200061022","article-title":"Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT).","volume":"256","author":"Stamler","year":"1986","journal-title":"JAMA"},{"key":"R5-20250619","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJM199511163332001","article-title":"Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia.","volume":"333","author":"Shepherd","year":"1995","journal-title":"New Engl J Med"},{"key":"R6-20250619","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1001\/jama.279.20.1615","article-title":"Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS\/TexCAPS. Air Force\/Texas Coronary Atherosclerosis Prevention Study.","volume":"279","author":"Downs","year":"1998","journal-title":"JAMA"},{"key":"R7-20250619","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1001\/jama.291.9.1071","article-title":"Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial.","volume":"291","author":"Nissen","year":"2004","journal-title":"JAMA"},{"key":"R8-20250619","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Intensive versus moderate lipid lowering with statins after acute coronary syndromes.","volume":"350","author":"Cannon","year":"2004","journal-title":"N Engl J Med"},{"key":"R9-20250619","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Cholesterol Treatment Trialists. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"R10-20250619","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1016\/S0140-6736(12)61770-X","article-title":"Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin\/Kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study.","volume":"380","author":"Giugliano","year":"2012","journal-title":"Lancet"},{"key":"R11-20250619","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1056\/NEJMoa1201832","article-title":"Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia.","volume":"367","author":"Roth","year":"2012","journal-title":"N Engl J Med"},{"key":"R12-20250619","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.","volume":"360","year":"2002","journal-title":"Lancet"},{"key":"R13-20250619","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1006\/abbi.1996.0030","article-title":"Inhibitors of cholesterol biosynthesis increase hepatic low-density lipoprotein receptor protein degradation.","volume":"325","author":"Ness","year":"1996","journal-title":"Arch Biochem Biophys"},{"key":"R14-20250619","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1001\/jama.1996.03530260042029","article-title":"Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia.","volume":"275","author":"Bakker-Arkema","year":"1996","journal-title":"JAMA"},{"key":"R15-20250619","doi-asserted-by":"crossref","first-page":"e013225","DOI":"10.1161\/JAHA.119.013225","article-title":"Diagnosis and Treatment of Heterozygous Familial Hypercholesterolemia.","volume":"8","author":"McGowan","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"R16-20250619","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1161\/CIRCULATIONAHA.107.708388","article-title":"Variation in the 3-hydroxyl-3-methylglutaryl coenzyme a reductase gene is associated with racial differences in low-density lipoprotein cholesterol response to simvastatin treatment.","volume":"117","author":"Krauss","year":"2008","journal-title":"Circulation"},{"key":"R17-20250619","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1093\/ehjcvp\/pvw006","article-title":"Variability of low-density lipoprotein cholesterol response with different doses of atorvastatin, rosuvastatin, and simvastatin: results from VOYAGER.","volume":"2","author":"Karlson","year":"2016","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"R18-20250619","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jacc.2014.02.615","article-title":"Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials.","volume":"64","author":"Boekholdt","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"R19-20250619","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1161\/CIRCULATIONAHA.112.136101","article-title":"Effect of statins on skeletal muscle function.","volume":"127","author":"Parker","year":"2013","journal-title":"Circulation"},{"key":"R20-20250619","doi-asserted-by":"crossref","first-page":"n135","DOI":"10.1136\/bmj.n135","article-title":"Statin treatment and muscle symptoms: series of randomised, placebo controlled n-of-1 trials.","volume":"372","author":"Herrett","year":"2021","journal-title":"BMJ"},{"key":"R21-20250619","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10557-005-5686-z","article-title":"Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients\u2013the PRIMO study.","volume":"19","author":"Bruckert","year":"2005","journal-title":"Cardiovasc Drugs Ther"},{"key":"R22-20250619","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1016\/S0140-6736(17)31075-9","article-title":"Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial\u2014Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase.","volume":"389","author":"Gupta","year":"2017","journal-title":"Lancet"},{"key":"R23-20250619","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jacl.2022.05.068","article-title":"NLA scientific statement on statin intolerance: a new definition and key considerations for ASCVD risk reduction in the statin intolerant patient.","volume":"16","author":"Cheeley","year":"2022","journal-title":"J Clin Lipidol"},{"key":"R24-20250619","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1161\/ATV.0000000000000073","article-title":"Statin safety and associated adverse events: a scientific statement from the American Heart Association.","volume":"39","author":"Newman","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R25-20250619","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.ahj.2013.06.004","article-title":"Treatment strategies in patients with statin intolerance: the Cleveland Clinic experience.","volume":"166","author":"Mampuya","year":"2013","journal-title":"Am Heart J"},{"key":"R26-20250619","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.atherosclerosis.2012.02.016","article-title":"Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials.","volume":"223","author":"Morrone","year":"2012","journal-title":"Atherosclerosis"},{"key":"R27-20250619","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes.","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"R28-20250619","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet"},{"key":"R29-20250619","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.jacc.2022.07.006","article-title":"2022 ACC expert consensus decision pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the american college of cardiology solution set oversight committee.","volume":"80","author":"Lloyd-Jones","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"R30-20250619","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.jacc.2018.04.054","article-title":"The evolving future of PCSK9 inhibitors.","volume":"72","author":"Rosenson","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"R31-20250619","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1161\/CIRCULATIONAHA.112.144055","article-title":"Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial.","volume":"126","author":"Raal","year":"2012","journal-title":"Circulation"},{"key":"R32-20250619","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1016\/S0140-6736(12)61771-1","article-title":"Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin\/Kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study.","volume":"380","author":"Koren","year":"2012","journal-title":"Lancet"},{"key":"R33-20250619","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1001\/jama.2016.3608","article-title":"Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 Randomized Clinical Trial.","volume":"315","author":"Nissen","year":"2016","journal-title":"JAMA"},{"key":"R34-20250619","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.","volume":"372","author":"Robinson","year":"2015","journal-title":"N Engl J Med"},{"key":"R35-20250619","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease.","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"R36-20250619","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome.","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"R37-20250619","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1056\/NEJMoa1614062","article-title":"Lipid-reduction variability and antidrug-antibody formation with bococizumab.","volume":"376","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"R38-20250619","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1161\/CIRCULATIONAHA.122.061620","article-title":"Long-term evolocumab in patients with established atherosclerotic cardiovascular disease.","volume":"146","author":"O\u2019Donoghue","year":"2022","journal-title":"Circulation"},{"key":"R39-20250619","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2165\/11584310-000000000-00000","article-title":"A 50-week extension study on the safety and efficacy of colesevelam in adults with primary hypercholesterolemia.","volume":"10","author":"Davidson","year":"2010","journal-title":"Am J Cardiovasc Drugs"},{"key":"R40-20250619","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/S0002-9343(01)00638-6","article-title":"Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia.","volume":"110","author":"Knapp","year":"2001","journal-title":"Am J Med"},{"key":"R41-20250619","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1001\/archinte.159.16.1893","article-title":"Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects.","volume":"159","author":"Davidson","year":"1999","journal-title":"Arch Intern Med"},{"key":"R42-20250619","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jama.1984.03340270029025","article-title":"The Lipid Research Clinics Coronary Primary Prevention Trial Results: I. Reduction in Incidence of Coronary Heart Disease.","volume":"251","year":"1984","journal-title":"JAMA"},{"key":"R43-20250619","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1161\/CIRCGENETICS.114.000952","article-title":"Effect of bile acid sequestrants on the risk of cardiovascular events: a mendelian randomization analysis.","volume":"8","author":"Ross","year":"2015","journal-title":"Circ Cardiovasc Genet"},{"key":"R44-20250619","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.jacl.2015.03.003","article-title":"Use of ETC-1002 to treat hypercholesterolemia in patients with statin intolerance.","volume":"9","author":"Thompson","year":"2015","journal-title":"J Clin Lipidol"},{"key":"R45-20250619","doi-asserted-by":"crossref","first-page":"e011662","DOI":"10.1161\/JAHA.118.011662","article-title":"Efficacy and safety of bempedoic acid in patients with hypercholesterolemia and statin intolerance.","volume":"8","author":"Laufs","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"R46-20250619","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.atherosclerosis.2018.06.002","article-title":"Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: a randomized, placebo-controlled study.","volume":"277","author":"Ballantyne","year":"2018","journal-title":"Atherosclerosis"},{"key":"R47-20250619","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1056\/NEJMoa1803917","article-title":"Safety and efficacy of bempedoic acid to reduce LDL cholesterol.","volume":"380","author":"Ray","year":"2019","journal-title":"N Engl J Med"},{"key":"R48-20250619","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1177\/2047487319864671","article-title":"Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy.","volume":"27","author":"Ballantyne","year":"2020","journal-title":"Eur J Prev Cardiol"},{"key":"R49-20250619","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1097\/FJC.0000000000001053","article-title":"Inclisiran: a novel agent for lowering apolipoprotein B-containing Lipoproteins.","volume":"78","author":"Warden","year":"2021","journal-title":"J Cardiovasc Pharmacol"},{"key":"R50-20250619","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJMoa1913805","article-title":"Inclisiran for the treatment of heterozygous familial hypercholesterolemia.","volume":"382","author":"Raal","year":"2020","journal-title":"N Engl J Med"},{"key":"R51-20250619","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1615758","article-title":"Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol.","volume":"376","author":"Ray","year":"2017","journal-title":"N Engl J Med"},{"key":"R52-20250619","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol.","volume":"382","author":"Ray","year":"2020","journal-title":"N Engl J Med"},{"key":"R53-20250619","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1161\/CIRCULATIONAHA.113.001292","article-title":"Lomitapide and Mipomersen.","volume":"129","author":"Rader","year":"2014","journal-title":"Circulation"},{"key":"R54-20250619","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1016\/j.jacc.2013.07.081","article-title":"Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial.","volume":"62","author":"Thomas","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"R55-20250619","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(10)60284-X","article-title":"Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial.","volume":"375","author":"Raal","year":"2010","journal-title":"Lancet"},{"key":"R56-20250619","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.jacl.2016.04.013","article-title":"Long-term mipomersen treatment is associated with a reduction in cardiovascular events in patients with familial hypercholesterolemia.","volume":"10","author":"Duell","year":"2016","journal-title":"J Clin Lipidol"},{"key":"R57-20250619","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(12)61731-0","article-title":"Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study.","volume":"381","author":"Cuchel","year":"2013","journal-title":"Lancet"},{"key":"R58-20250619","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1056\/NEJMoa2031049","article-title":"Evinacumab in patients with refractory hypercholesterolemia.","volume":"383","author":"Rosenson","year":"2020","journal-title":"N Engl J Med"},{"key":"R59-20250619","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa2004215","article-title":"Evinacumab for homozygous familial hypercholesterolemia.","volume":"383","author":"Raal","year":"2020","journal-title":"N Engl J Med"},{"key":"R60-20250619","doi-asserted-by":"crossref","first-page":"e468","DOI":"10.1161\/CIR.0000000000000456","article-title":"Recommendations for management of clinically significant drug-drug interactions with statins and select agents used in patients with cardiovascular disease: a scientific statement from the American Heart Association.","volume":"134","author":"Wiggins","year":"2016","journal-title":"Circulation"},{"key":"R61-20250619","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1161\/CIR.0b013e3182160726","article-title":"Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association.","volume":"123","author":"Miller","year":"2011","journal-title":"Circulation"},{"key":"R62-20250619","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/j.amjcard.2008.02.029","article-title":"Mechanism of action of niacin.","volume":"101","author":"Kamanna","year":"2008","journal-title":"Am J Cardiol"},{"key":"R63-20250619","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1001\/archinte.1994.00420140051007","article-title":"Comparative effects of lovastatin and niacin in primary hypercholesterolemia. A prospective trial.","volume":"154","author":"Illingworth","year":"1994","journal-title":"Arch Intern Med"},{"key":"R64-20250619","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1300955","article-title":"Effects of extended-release niacin with laropiprant in high-risk patients.","volume":"371","author":"Landray","year":"2014","journal-title":"N Engl J Med"},{"key":"R65-20250619","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.","volume":"365","author":"Boden","year":"2011","journal-title":"N Engl J Med"},{"key":"R66-20250619","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1001\/archinte.163.5.553","article-title":"Risk for myopathy with statin therapy in high-risk patients.","volume":"163","author":"Ballantyne","year":"2003","journal-title":"Arch Intern Med"},{"key":"R67-20250619","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1001\/archinte.1994.00420140015002","article-title":"Nicotinic acid as a lipoprotein-altering agent. Therapy directed by the primary physician.","volume":"154","author":"Probstfield","year":"1994","journal-title":"Arch Intern Med"},{"key":"R68-20250619","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1016\/j.amjcard.2008.02.056","article-title":"Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction.","volume":"101","author":"Lu","year":"2008","journal-title":"Am J Cardiol"},{"key":"R69-20250619","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.amjcard.2017.06.015","article-title":"Comparison of low-dose statin versus low-dose statin + armolipid plus in high-intensity statin-intolerant patients with a previous coronary event and percutaneous coronary intervention (ADHERENCE Trial).","volume":"120","author":"Marazzi","year":"2017","journal-title":"Am J Cardiol"},{"key":"R70-20250619","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jacc.2018.04.040","article-title":"The Role of nutraceuticals in statin intolerant patients.","volume":"72","author":"Banach","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"R71-20250619","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1056\/NEJMoa1706444","article-title":"Effects of anacetrapib in patients with atherosclerotic vascular disease.","volume":"377","author":"Bowman","year":"2017","journal-title":"N Engl J Med"},{"key":"R72-20250619","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1038\/s41591-022-01936-7","article-title":"Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trial.","volume":"28","author":"Nicholls","year":"2022","journal-title":"Nat Med"},{"key":"R73-20250619","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1056\/NEJMoa1905239","article-title":"Lipoprotein(a) reduction in persons with cardiovascular disease.","volume":"382","author":"Tsimikas","year":"2020","journal-title":"N Engl J Med"},{"key":"R74-20250619","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1001\/jama.2022.5050","article-title":"Single ascending dose study of a short interfering rna targeting lipoprotein(a) production in individuals with elevated plasma lipoprotein(a) levels.","volume":"327","author":"Nissen","year":"2022","journal-title":"JAMA"},{"key":"R75-20250619","doi-asserted-by":"crossref","first-page":"e003294","DOI":"10.1161\/JAHA.116.003294","article-title":"Systematic review of low-density lipoprotein cholesterol apheresis for the treatment of familial hypercholesterolemia.","volume":"5","author":"Wang","year":"2016","journal-title":"J Am Hear Assoc"},{"key":"R76-20250619","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1056\/NEJM198412273112603","article-title":"Liver transplantation to provide low-density-lipoprotein receptors and lower plasma cholesterol in a child with homozygous familial hypercholesterolemia.","volume":"311","author":"Bilheimer","year":"1984","journal-title":"N Engl J Med"},{"key":"R77-20250619","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1038\/nm1195-1148","article-title":"A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia.","volume":"1","author":"Grossman","year":"1995","journal-title":"Nat Med"},{"key":"R78-20250619","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1161\/01.CIR.103.9.1274","article-title":"Long-term stable correction of low-density lipoprotein receptor-deficient mice with a helper-dependent adenoviral vector expressing the very low-density lipoprotein receptor.","volume":"103","author":"Oka","year":"2001","journal-title":"Circulation"},{"key":"R79-20250619","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1161\/CIRCRESAHA.115.304008","article-title":"AAV vectors expressing LDLR gain-of-function variants demonstrate increased efficacy in mouse models of familial hypercholesterolemia.","volume":"115","author":"Somanathan","year":"2014","journal-title":"Circ Res"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000498","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T16:02:49Z","timestamp":1750348969000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000498"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,7]]},"references-count":79,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000000498","relation":{},"ISSN":["1061-5377"],"issn-type":[{"value":"1061-5377","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6,7]]}}}